Kissei Pharmaceutical Halts New Administration of Key Vasculitis Drug Tabneos Following 20 Deaths
Kissei Pharmaceutical has issued an urgent request to halt the new administration of Tabneos, a flagship treatment for vasculitis, after reports emerged of 20 deaths following the drug’s use. The move signals a critical safety pivot for one of the company’s primary pharmaceutical offerings.
The safety concerns surrounding the vasculitis medication have extended to international regulatory bodies. The U.S. Food and Drug Administration (FDA) has reportedly proposed the withdrawal of the drug’s approval, further compounding the pressure on the Japanese drugmaker.
As a cornerstone of Kissei Pharmaceutical’s product portfolio, the suspension of new prescriptions for Tabneos represents a significant operational and financial risk. The company is now urging healthcare providers to refrain from starting new patients on the therapy.
The decision to restrict the drug’s use underscores the volatility inherent in high-stakes pharmaceutical development, where late-stage safety signals can abruptly jeopardize a company’s primary revenue drivers. According to company requests, the priority has shifted to mitigating further risk by limiting new exposures to the drug.
Industry observers note that the potential loss of FDA approval in the United States, combined with the domestic halt on new administrations, could have a meaningful impact on Kissei’s market positioning within the vasculitis treatment space. The company continues to manage the fallout from the 20 reported fatalities associated with the treatment.
